LRMRHIGH SIGNALFINANCIAL10-K

LRMR suffered severe financial deterioration with net losses more than doubling to $165.7M while stockholders' equity collapsed 55% despite raising $107.6M in February 2026.

The company is burning through cash at an accelerated rate with operating cash outflows increasing 60% to $113.2M, indicating their drug development costs are escalating rapidly. Despite recently raising over $100M, their runway only extends to Q2 2027, creating potential financing pressure if their June 2026 BLA submission faces delays or rejection.

Comparing 2026-03-19 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

LRMR's financials show a company in rapid cash burn mode with R&D expenses more than doubling to $154.2M, driving net losses to $165.7M and destroying over half of stockholders' equity. While they raised capital (evidenced by increased cash and current liabilities from the February 2026 offering), the accelerating operating cash outflows of $113.2M demonstrate unsustainable burn rates. The dramatic increase in current liabilities alongside the equity destruction suggests significant dilution from the recent fundraising, creating a precarious financial position heading into their critical BLA submission.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+166%
$24.4M→$64.8M

Current liabilities surged 166% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
+157.1%
$33.2M→$85.4M

Cash position surged 157.1% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
+138.5%
$28.4M→$67.8M

Liabilities grew 138.5% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+110.5%
$73.3M→$154.2M

R&D investment increased 110.5% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-105.5%
-$80.6M→-$165.7M

Net income declined 105.5% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-89.8%
-$90.9M→-$172.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Capital Expenditure
Cash Flow
-82.3%
$515K→$91K

Capex reduced 82.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-60%
-$70.8M→-$113.2M

Operating cash flow fell 60% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-54.6%
$171.8M→$78.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Debt
Balance Sheet
-27.3%
$20.0M→$14.5M

Debt reduced 27.3% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-24
ADDED
As of March 17, 2026, the registrant had 103,882,937 shares of Common Stock, $0.001 par value per share, outstanding.
You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the U.S.
As of December 31, 2025, we had $136.9 million of cash, cash equivalents and marketable securities.
Together with the $107.6 million in net proceeds from our recently completed February 2026 public offering, we expect this will fund operations into the second quarter of 2027.
We are targeting to submit a BLA to the FDA in June 2026 for marketing approval of nomlabofusp using the accelerated approval pathway; however, there can be no assurance that the FDA will approve our BLA submission for accelerated approval.
+7 more — sign up free →
REMOVED
As of March 20, 2025, the registrant had 64,027,892 shares of Common Stock, $0.001 par value per share, outstanding.
As of December 31, 2024, we have $183.5 million of cash, cash equivalents and marketable securities which we expect will fund operations into the second quarter of 2026.
and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security laws, Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia ( FA ).
As of December 31, 2024, we had cash, cash equivalents and marketable securities of $183.5 million, which we anticipate will fund operations into the second quarter of 2026.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →